缺血性卒中后5年内靶向LDL胆固醇<70 mg/dL的获益
Background and Purpose- The TST trial (Treat Stroke to Target) evaluated the benefit of targeting a LDL (low-density lipoprotein) cholesterol of <70 mg/dL to reduce the risk of cardiovascular events in 2860 patients with ischemic stroke with atherosclerotic stenosis of cerebral v…
要点
- 靶向LDL-C<70 mg/dL可降低主要血管事件风险
- 每治疗30例可避免1例主要血管事件
- 未观察到颅内出血风险增加
核心结论
- 对于有动脉粥样硬化证据的缺血性卒中患者,靶向LDL胆固醇<70 mg/dL并维持5.3年可减少后续主要血管事件,且不增加颅内出血。
主要发现
- 主要终点事件在<70 mg/dL组和100±10 mg/dL组分别发生9.6%和12.9%(HR 0.74, 95%CI 0.57-0.94; P=0.019)。
- 脑梗死或TIA后紧急颈动脉血运重建减少27%(P=0.046)。
- 脑梗死或颅内出血减少28%(P=0.023)。
- 主要终点或颅内出血减少25%(P=0.021)。
- 颅内出血两组分别13例和11例(HR 1.17, 95%CI 0.53-2.62; P=0.70)。
关键数值与推荐
- 靶向LDL胆固醇<70 mg/dL(1.8 mmol/L)与100±10 mg/dL(90-110 mg/dL,2.3-2.8 mmol/L)比较。
- 主要终点为缺血性卒中、心肌梗死、需紧急冠状动脉或颈动脉血运重建的新发症状及血管性死亡的复合终点。
- 需治疗人数(NNT)为30。
临床怎么用
- 对于有动脉粥样硬化证据的缺血性卒中患者,可考虑将LDL胆固醇降至<70 mg/dL以降低主要血管事件风险。
局限性
- 本报告仅限法国队列,韩国队列随访时间较短未纳入。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- The TST trial (Treat Stroke to Target) evaluated the benefit of targeting a LDL (low-density lipoprotein) cholesterol of <70 mg/dL to reduce the risk of cardiovascular events in 2860 patients with ischemic stroke with atherosclerotic stenosis of cerebral vasculature or aortic arch plaque >4 mm, in a French and Korean population. The follow-up lasted a median of 5.3 years in French patients (similar to the median follow-up time in the SPARCL trial [Stroke Prevention by Aggressive Reduction in Cholesterol Level]) and 2.0 years in Korean patients. Exposure duration to statin is a well-known driver for cardiovascular risk reduction. We report here the TST results in the French cohort. Methods- One thousand seventy-three French patients were assigned to <70 mg/dL (1.8 mmol/L) and 1075 to 100±10 mg/dL (90-110 mg/dL, 2.3-2.8 mmol/L). To achieve these goals, investigators used the statin and dosage of their choice and added ezetimibe on top if needed. The primary outcome was the composite of ischemic stroke, myocardial infarction, new symptoms requiring urgent coronary or carotid revascularization and vascular death. Results- After a median follow-up of 5.3 years, the achieved LDL cholesterol was 66 (1.69 mmol/L) and 96 mg/dL (2.46 mmol/L) on average, respectively. The primary end point occurred in 9.6% and 12.9% of patients, respectively (HR, 0.74 [95% CI, 0.57-0.94]; P=0.019). Cerebral infarction or urgent carotid revascularization following transient ischemic attack was reduced by 27% (P=0.046). Cerebral infarction or intracranial hemorrhage was reduced by 28% (P=0.023). The primary outcome or intracranial hemorrhage was reduced by 25% (P=0.021). Intracranial hemorrhages occurred in 13 and 11 patients, respectively (HR, 1.17 [95% CI, 0.53-2.62]; P=0.70). Conclusions- After an ischemic stroke of documented atherosclerotic origin, targeting a LDL cholesterol of <70 mg/dL during 5.3 years avoided 1 subsequent major vascular event in 4 (number needed to treat of 30) and no increase in intracranial hemorrhage. Registration- URL: https://www.clinicaltrials.gov; Unique identifier: NCT01252875.
引用
- Amarenco P, Kim JS, Labreuche J, et al. Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol <70 mg/dL During 5 Years After Ischemic Stroke. Stroke. 2020. PMID: 32078484. doi:10.1161/STROKEAHA.119.028718
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。